Table 3.
Number of resistant isolates (%) and range of MICs in μg/mL | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
Isolates | AZI | CIP | ERY | GEN | TET | FFN | NAL | TEL | CLI | |
C. jejuni | Total | 6 (26)a | 7 (30.4)a | 3 (13)a | 2 (8.7)a | 19 (82.6)a | 0 | 3 (13.0)a | 1 (4.3)a | 7 (30.4)a |
(n=23) | 64* | 8–16 | 64 | 8–16 | 32–64 | 64 | 8 | 16 | ||
Farm A | 5(29.4) | 7 (38.9) | 3 (16.7) | 1 (5.6) | 14 (82.3) | 0 | 1 (5.8) | 1 (5.6) | 6 (35.2) | |
(n=17) | 64 | 8–16 | 64 | 8 | 32–64 | 64 | 8 | 16 | ||
Farm B | 1 (33.3) | 0 | 0 | 1 (33.3) | 3 (100) | 0 | 2 (66.7) | 0 | 1 (33.3) | |
(n=3) | 64* | 16 | 32–64 | 64 | 16 | |||||
Farm C | 0 | 0 | 0 | 0 | 2 (66.7) | 0 | 0 | 0 | 0 | |
(n=3) | 64 | |||||||||
C. coli | Total | 36 (48)a | 34 (45.3)a | 15 (20)a | 7 (9.3)a | 74 (100.0)b | 0 | 6 (8)a | 10 (13.3)a | 33 (44)a |
(n=75) | 8–64 | 8–32 | 32–64 | 8–32 | 32–64 | 64 | 8 | 8–16 | ||
Farm A | 10 (38.5)c | 21 (80.8)c | 5 (19.2)c | 2 (7.7)c | 26 (100.0)c | 0 | 5 (19.2)c | 2 (7.7)c | 9 (34.6)c | |
(n=26) | 8–64 | 8–32 | 32–64 | 16–32 | 32–64 | 64 | 8 | 8–16 | ||
Farm B | 14 (56.0)c | 4 (16.0)d | 9 (36.0)d | 2 (8.0)c | 25 (100.0)c | 0 | 0d | 8 (32.0)d | 10 (40.0)c | |
(n=25) | 8–64 | 8–32 | 64 | 8–16 | 32–64 | 8 | 8–16 | |||
Farm C | 12 (50.0)c | 9 (37.5)e | 1 (4.2)c | 3 (12.5)c | 23 (95.8)c | 0 | 1 (4.2)c | 0c | 14 (58.3)c | |
(n=24) | 8–64 | 8–32 | 64 | 16 | 32–64 | 64 | 8–16 |
MIC ranges of antimicrobials for the resistant isolates.
For each antimicrobial, numbers in the same row with different superscript letters were significantly different (p<0.05), while numbers with the same letters did not differ significantly (chi-square test and Fisher's exact two-tailed test).
Resistance breakpoints: AZI, ≥8 μg/mL; CIP, ≥4 μg/mL; CLI, ≥8 μg/mL; ERY, ≥32 μg/mL; GEN, ≥8 μg/mL; NAL, ≥64 μg/mL; TEL, ≥8 μg/mL; FEN, ≥8 μg/mL; TET, ≥16 μg/mL.
AZI, azithromycin; CIP, ciprofloxacin; CLI, clindamycin; ERY, erythromycin; FFN, florfenicol; GEN, gentamicin; NAL, nalidixic acid; TEL, telithromycin; TET, tetracycline.